Attached files

file filename
10-Q - FORM 10-Q - AGENUS INCd10q.htm
EX-4.6 - WAIVER OF RIGHTS UPON ISSUANCE OF OTHER SECURITIES DATED AUGUST 3, 2009 - AGENUS INCdex46.htm
EX-4.3 - WAIVER OF RIGHTS UPON ISSUANCE OF OTHER SECURITIES DATED JULY 29, 2009 - AGENUS INCdex43.htm
EX-10.7 - SUPPLY AGREEMENT - AGENUS INCdex107.htm
EX-10.4 - FIRST AMENDMENT TO EMPLOYMENT AGREEMENT DATED JULY 2, 2009 FOR KERRY WENTWORTH - AGENUS INCdex104.htm
EX-10.6 - NOTICE OF ASSIGNMENT OF AMENDED AND RESTATED LICENSE AGREEMENT - AGENUS INCdex106.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 302 - AGENUS INCdex311.htm
EX-10.5 - AMENDED AND RESTATED LICENSE AGREEMENT - AGENUS INCdex105.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - AGENUS INCdex312.htm
EX-10.1 - FIRST AMENDMENT TO EMPLOYMENT AGREEMENT DATED JULY 2, 2009 FOR GARO ARMEN - AGENUS INCdex101.htm
EX-10.2 - FIRST AMENDMENT TO EMPLOYMENT AGREEMENT DATED JULY 2, 2009 FOR SHALINI SHARP - AGENUS INCdex102.htm
EX-10.3 - FIRST AMENDMENT TO EMPLOYMENT AGREEMENT DATED JULY 2, 2009 FOR KAREN VALENTINE - AGENUS INCdex103.htm

Exhibit 32.1

Certification

Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Antigenics Inc. (the “Company”) for the quarterly period ended September 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned to his/her knowledge hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

 

  (i) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/    GARO H. ARMEN, PH.D.

Garo H. Armen, Ph.D.

Chief Executive Officer

/s/    SHALINI SHARP

Shalini Sharp

Chief Financial Officer

Date: November 9, 2009

A signed original of this written statement required by Section 906 has been provided to Antigenics Inc. and will be retained by Antigenics Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished to the Securities and Exchange Commission as an exhibit to the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2009 and should not be considered filed as part of the Quarterly Report on Form 10-Q.